<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0026-1742</journal-id>
<journal-title><![CDATA[Revista de la Facultad de Medicina (México)]]></journal-title>
<abbrev-journal-title><![CDATA[Rev. Fac. Med. (Méx.)]]></abbrev-journal-title>
<issn>0026-1742</issn>
<publisher>
<publisher-name><![CDATA[Universidad Nacional Autónoma de México, Facultad de Medicina]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0026-17422024000400043</article-id>
<article-id pub-id-type="doi">10.22201/fm.24484865e.2024.67.4.07</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Opioides, sobredosis y los desafíos de la reducción de daños como estrategia eficiente en el campo de la salud pública]]></article-title>
<article-title xml:lang="en"><![CDATA[Opioids, Overdose and Harm Reduction as an Efficient Strategy for Public Healt]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Villafuerte García]]></surname>
<given-names><![CDATA[Adriana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Hernández Martínez]]></surname>
<given-names><![CDATA[Luis Javier]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Domínguez Ruíz]]></surname>
<given-names><![CDATA[Ángel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Guzmán]]></surname>
<given-names><![CDATA[Karla Mayte]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rafful]]></surname>
<given-names><![CDATA[Claudia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Nacional Autónoma de México Facultad de Medicina ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Universidad Nacional Autónoma de México Facultad de Medicina ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Universidad Nacional Autónoma de México Facultad de Psicología ]]></institution>
<addr-line><![CDATA[Ciudad de México ]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>08</month>
<year>2024</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>08</month>
<year>2024</year>
</pub-date>
<volume>67</volume>
<numero>4</numero>
<fpage>43</fpage>
<lpage>56</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0026-17422024000400043&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0026-17422024000400043&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0026-17422024000400043&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen El tráfico y el consumo de drogas es un desafío global que afecta a todas las sociedades en diferentes formas y dimensiones; su carácter multidimensional tiene un alto impacto en la salud de las poblaciones y en la economía de los países. Tan solo en 2021, se estimó que 296 millones de personas q q q consumieron drogas. Durante años, la política mundial de salud en materia de drogas estuvo centrada en la prohibición; sin embargo, en la actualidad se sabe que un enfoque de reducción de riesgos y daños, lejos de rechazar la abstinencia, reduce los efectos negativos del consumo de sustancias legales e ilegales, incluidas las muertes por sobredosis, lo cual trae grandes beneficios a la salud y al funcionamiento social de quienes las consumen. Este artículo brinda una comprensión integral del consumo de opioides, específicamente fentanilo, y recalca la necesidad de abordarlo a través de un enfoque integral que combine estrategias basadas en la evidencia, bajo el reconocimiento de que la salud es un derecho humano fundamental y una condición indispensable para el desarrollo.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Drug trafficking and use is a global challenge that affects all societies in different forms and dimensions. Its multidimensional nature has a high impact on the health of populations and the economies of countries. In 2021, it was estimated that 296 million people used drugs. For years, global health policy on drugs was focused on prohibition, however, we now know that a harm reduction approach, far from rejecting abstinence, reduces the negative effects of legal and illegal substance use, including overdose-related deaths. Harm reduction brings great health benefits and improves social functioning of those engaged in substance use. This article provides a comprehensive understanding of opioid use, specifically fentanyl, and emphasizes the need to address it through a comprehensive approach that combines evidence-based strategies, recognizing that health is a fundamental human right and an essential condition for development.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Opioides]]></kwd>
<kwd lng="es"><![CDATA[fentanilo]]></kwd>
<kwd lng="es"><![CDATA[reducción de daños]]></kwd>
<kwd lng="es"><![CDATA[abuso de sustancias]]></kwd>
<kwd lng="es"><![CDATA[sobredosis]]></kwd>
<kwd lng="en"><![CDATA[Opioids]]></kwd>
<kwd lng="en"><![CDATA[fentanyl]]></kwd>
<kwd lng="en"><![CDATA[harm reduction]]></kwd>
<kwd lng="en"><![CDATA[substance abuse]]></kwd>
<kwd lng="en"><![CDATA[overdose]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<source><![CDATA[World Drug Report]]></source>
<year>2023</year>
<publisher-name><![CDATA[United Nations]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="book">
<source><![CDATA[La dimensión de salud pública del problema mundial de las drogas]]></source>
<year>2022</year>
<publisher-name><![CDATA[Organización Mundial de la Salud]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<collab>CONADIC</collab>
<source><![CDATA[Informe sobre la situación de las Drogas en México y su Atención Integral]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="book">
<source><![CDATA[Defunciones por consumo de sustancias psicoactivas en 2019]]></source>
<year>2019</year>
<publisher-name><![CDATA[Observatorio mexicano de salud mental y consumo de drogas]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Magis Rodríguez]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Villafuerte García]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Angulo Corral M de]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Pacheco Bufanda]]></surname>
<given-names><![CDATA[LI]]></given-names>
</name>
<name>
<surname><![CDATA[Salazar Arriola]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Ramos Rodríguez]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Sobredosis fatales y no fatales por consumo de opioides en el contexto de la pandemia por COVID- 19 en el norte de México]]></article-title>
<source><![CDATA[Revista UNAM]]></source>
<year>2022</year>
<volume>3</volume>
<page-range>7</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goodman-Meza]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Slim]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Angulo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzales Nieto]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Cambou]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Lorea]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Drug and Alcohol Dependence Report]]></source>
<year>2022</year>
<volume>2</volume>
<page-range>100021</page-range><publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<collab>CONADIC</collab>
<source><![CDATA[nforme de la demanda y oferta de fentanilo en México: generalidades y situación actual]]></source>
<year>2024</year>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="">
<article-title xml:lang=""><![CDATA[Defunciones por consumo de sustancias psicoactivas en 2019]]></article-title>
<source><![CDATA[Observatorio mexicano de salud mental y consumo de drogas]]></source>
<year>2019</year>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ospina Escobar]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<source><![CDATA[Ambientes de riesgo al VIH entre varones que se inyectan en Tijuana, Ciudad Juárez y Hermosillo, un análisis corporativo]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Magri]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Manchiero]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Dantas]]></surname>
<given-names><![CDATA[BP]]></given-names>
</name>
<name>
<surname><![CDATA[da Silva Nunes]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Vaz Gago Prata]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Domingos]]></surname>
<given-names><![CDATA[DEA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hepatitis C Among People Who Inject Drugs PWID in Latin America and the Caribbean: A Meta-Analysis of Prevalence Over Three Decades]]></article-title>
<source><![CDATA[J Stud Alcohol Drugs]]></source>
<year>2023</year>
<volume>84</volume>
<page-range>118-27</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gropper]]></surname>
<given-names><![CDATA[AM.]]></given-names>
</name>
</person-group>
<source><![CDATA[Anestesia]]></source>
<year>2021</year>
<edition>8a</edition>
<page-range>680-745</page-range><publisher-name><![CDATA[Elsevier]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Álvarez]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Farré]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Farmacología de los opioides]]></article-title>
<source><![CDATA[Adicciones]]></source>
<year>2005</year>
<volume>17</volume>
<page-range>21-40</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cruz]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Rafful]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A brief history of opioids and the evolution of concepts associated with substance use disorders]]></article-title>
<person-group person-group-type="editor">
<name>
<surname><![CDATA[Cruz]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
</person-group>
<source><![CDATA[Opioids]]></source>
<year>2022</year>
<page-range>3-23</page-range><publisher-loc><![CDATA[Cham ]]></publisher-loc>
<publisher-name><![CDATA[Springer]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kibaly]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cahill]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Law]]></surname>
<given-names><![CDATA[P-Y.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Non-nociceptive roles of opioids in the CNS: opioids&#8217; effects on neurogenesis, learning, memory and affect]]></article-title>
<source><![CDATA[Nat Rev Neurosci]]></source>
<year>2019</year>
<volume>20</volume>
<page-range>5-18</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Comer]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Cahill]]></surname>
<given-names><![CDATA[CM.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fentanyl: Receptor pharmacology, abuse potential, and implications for treatment]]></article-title>
<source><![CDATA[Neurosci Biobehav Rev]]></source>
<year>2019</year>
<volume>106</volume>
<page-range>49-57</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Han]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Yan]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Khan]]></surname>
<given-names><![CDATA[MZ]]></given-names>
</name>
<name>
<surname><![CDATA[Yuan]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Lu]]></surname>
<given-names><![CDATA[L.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The rising crisis of illicit fentanyl use, overdose, and potential therapeutic strategies]]></article-title>
<source><![CDATA[Transl Psychiatry]]></source>
<year>2019</year>
<volume>9</volume>
<page-range>282</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Patocka]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Oleksak]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Jelinkova]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Nepovimova]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Spicanova]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fentanyl and its derivatives: Pain-killers or man-killers?]]></article-title>
<source><![CDATA[Heliyon]]></source>
<year>2024</year>
<volume>10</volume>
</nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="">
<source><![CDATA[El fentanilo: Una pastilla mata | Salud y Servicios Humanos de Texas]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Suzuki]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[El-Haddad]]></surname>
<given-names><![CDATA[S.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A review: Fentanyl and non-pharmaceutical fentanyls]]></article-title>
<source><![CDATA[Drug and Alcohol Dependence]]></source>
<year>2017</year>
<volume>171</volume>
<page-range>107-16</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="">
<source><![CDATA[Fentanyl Facts]]></source>
<year>2024</year>
</nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Fentanyl Overdose Symptoms, Dangers &amp; Treatment [Internet]]]></article-title>
<source><![CDATA[American Addiction Centers]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Fentanilo, entre crisis de salud y seguridad]]></article-title>
<source><![CDATA[El economista]]></source>
<year>2023</year>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="">
<collab>World Drug Report</collab>
<source><![CDATA[United Nations: Office on Drugs and Crime]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grillo]]></surname>
<given-names><![CDATA[I.]]></given-names>
</name>
</person-group>
<source><![CDATA[Fentanyl Kills Mexico&#8217;s Opium Trade]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="">
<source><![CDATA[Coordinación de Comunicación Social - Contrastan decomisos de fentanilo fabricado ilícitamente en México y EEUU, destaca estudio del IBD]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fleiz]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Arredondo]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Chavez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Pacheco]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Segovia]]></surname>
<given-names><![CDATA[LA]]></given-names>
</name>
<name>
<surname><![CDATA[Villatoro]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Fentanyl is used in Mexico&#8217;s northern border: current challenges for drug health policies]]></article-title>
<source><![CDATA[Addiction]]></source>
<year>2020</year>
<volume>115</volume>
<page-range>778-81</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Menció]]></surname>
<given-names><![CDATA[SD.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tendencias actuales de producción y consumo de drogas ilícitas en México]]></article-title>
<source><![CDATA[Anuario Mexicano de Asuntos Globales]]></source>
<year>2023</year>
<volume>1</volume>
<page-range>707-14</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferraris]]></surname>
<given-names><![CDATA[G.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Final histórico en la 67° reunión de la CND: ganó la reducción de daños]]></article-title>
<source><![CDATA[Revista Mate]]></source>
<year>2024</year>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Insúa]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Grijalvo]]></surname>
<given-names><![CDATA[J.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Programas de reducción de riesgos en atención a las drogodependencias: conceptos y acciones específicas]]></article-title>
<source><![CDATA[Papeles del Psicólogo]]></source>
<year>2000</year>
<page-range>33-45</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bosque-Prous]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Brugal]]></surname>
<given-names><![CDATA[MT.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intervenciones de reducción de daños en usuarios de drogas: situación actual y recomendaciones]]></article-title>
<source><![CDATA[Gac Sanit]]></source>
<year>2016</year>
<volume>30</volume>
<page-range>99-105</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bueno]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Latin American harm reduction network RELARD: Successes and challenges]]></article-title>
<source><![CDATA[ScienceDirect]]></source>
<year>2007</year>
<volume>1</volume>
</nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thomson]]></surname>
<given-names><![CDATA[N.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Harm reduction history, response, and current trends in Asia]]></article-title>
<source><![CDATA[J Food Drug Anal]]></source>
<year>2013</year>
<volume>21</volume>
<page-range>S113-6</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bosque-Prous]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Brugal]]></surname>
<given-names><![CDATA[MT.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intervenciones de reducción de daños en usuarios de drogas: situación actual y recomendaciones]]></article-title>
<source><![CDATA[Gac Sanit]]></source>
<year>2016</year>
<volume>30</volume>
<page-range>99-105</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="book">
<source><![CDATA[¿Qué es Reducción de Daños?]]></source>
<year></year>
<publisher-name><![CDATA[Harm Reduction International]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tizoc-Marquez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rivera-Fierro]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Rieke-Campoy]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Cruz-Palomares]]></surname>
<given-names><![CDATA[M.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reducción De Daños Como Estrategia Para El Uso Y Abuso De Sustancias En México: Desafíos Y Oportunidades]]></article-title>
<source><![CDATA[Ra Ximhai]]></source>
<year>2017</year>
<volume>13</volume>
<page-range>39-51</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Magis-Rodríguez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[García-Sánchez]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Marín-Navarrete]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Magis-Rodríguez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[García-Sánchez]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Marín-Navarrete]]></surname>
<given-names><![CDATA[R.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Harm reduction among people who inject drugs in Mexico]]></article-title>
<source><![CDATA[Salud mental]]></source>
<year>2018</year>
</nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Magis Rodríguez]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Barrientos Barcénas]]></surname>
<given-names><![CDATA[H.]]></given-names>
</name>
</person-group>
<source><![CDATA[VIH/SIDA y salud pública. Manual para personal de salud]]></source>
<year>2009</year>
<edition>egunda</edition>
</nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Valenzuela-Lara]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ponce-Ramos]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ruiz-Herrera]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[López-González]]></surname>
<given-names><![CDATA[A.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Impact of funding harm reduction programs for people who inject drugs in Mexico]]></article-title>
<source><![CDATA[Salud Mental]]></source>
<year>2019</year>
<volume>42</volume>
<page-range>157-63</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="">
<collab>Conadic</collab>
<source><![CDATA[Informe sobre la Situación de la Salud Mental y el Consumo de Sustancias Psicoactivas en México]]></source>
<year>2021</year>
</nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Strathdee]]></surname>
<given-names><![CDATA[S.A.]]></given-names>
</name>
<name>
<surname><![CDATA[Goodman-Meza]]></surname>
<given-names><![CDATA[D.]]></given-names>
</name>
<name>
<surname><![CDATA[Rafful]]></surname>
<given-names><![CDATA[C.]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Addressing opioid use disorder: Mexico&#8217;s step backwards]]></article-title>
<source><![CDATA[The Lancet Regional Health Americas]]></source>
<year>2023</year>
<page-range>100520</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="">
<collab>Coordinación de Comunicación Social</collab>
<source><![CDATA[Aprueba Comisión proyecto para eliminar naloxona de la lista de sustancias psicotrópicas]]></source>
<year></year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
